The Finnish trial of prostate cancer screening: where are we now?
2003; Wiley; Volume: 92; Issue: s2 Linguagem: Inglês
10.1111/j.1465-5101.2003.04397.x
ISSN1464-410X
AutoresPatrik Finne, Ulf‐Håkan Stenman, Liisa Määttänen, Tuukka Mäkinen, Teuvo L.J. Tammela, Pekka Martikainen, Mirja Ruutu, M. Ala‐Opas, J. Aro, Pekka J. Karhunen, Jorma Lahtela, Pekka Rissanen, Harri Juusela, Matti Hakama, Anssi Auvinen,
Tópico(s)Cancer, Lipids, and Metabolism
ResumoBJU InternationalVolume 92, Issue s2 p. 22-26 The Finnish trial of prostate cancer screening: where are we now? P. Finne, P. Finne Department of Clinical Chemistry, University of Helsinki, Helsinki, School of Public Health andSearch for more papers by this authorU.-H. Stenman, U.-H. Stenman Department of Clinical Chemistry, University of Helsinki, Helsinki,Search for more papers by this authorL. Määttänen, L. Määttänen Finnish Cancer Registry, Helsinki,Search for more papers by this authorT. Mäkinen, T. Mäkinen Division of Urology,Search for more papers by this authorT.L.J. Tammela, T.L.J. Tammela Division of Urology,Search for more papers by this authorP. Martikainen, P. Martikainen Department of Pathology, Centre for Laboratory Medicine, andSearch for more papers by this authorM. Ruutu, M. Ruutu Departments of Urology, andSearch for more papers by this author M. Ala-Opas, M. Ala-Opas Departments of Urology, andSearch for more papers by this authorJ. Aro, J. Aro Departments of Urology, andSearch for more papers by this authorP.J. Karhunen, P.J. Karhunen Department of Forensic Medicine and Research Unit of Clinical Chemistry, University of Tampere,Search for more papers by this authorJ. Lahtela, J. Lahtela Department of Internal Medicine, Tampere University Hospital, Tampere, andSearch for more papers by this authorP. Rissanen, P. Rissanen School of Public Health andSearch for more papers by this authorH. Juusela, H. Juusela Surgery, Jorvi Hospital, Helsinki University Central Hospital, Helsinki, FinlandSearch for more papers by this authorM. Hakama, M. Hakama Finnish Cancer Registry, Helsinki, School of Public Health andSearch for more papers by this author A. Auvinen, A. Auvinen School of Public Health andSearch for more papers by this author P. Finne, P. Finne Department of Clinical Chemistry, University of Helsinki, Helsinki, School of Public Health andSearch for more papers by this authorU.-H. Stenman, U.-H. Stenman Department of Clinical Chemistry, University of Helsinki, Helsinki,Search for more papers by this authorL. Määttänen, L. Määttänen Finnish Cancer Registry, Helsinki,Search for more papers by this authorT. Mäkinen, T. Mäkinen Division of Urology,Search for more papers by this authorT.L.J. Tammela, T.L.J. Tammela Division of Urology,Search for more papers by this authorP. Martikainen, P. Martikainen Department of Pathology, Centre for Laboratory Medicine, andSearch for more papers by this authorM. Ruutu, M. Ruutu Departments of Urology, andSearch for more papers by this author M. Ala-Opas, M. Ala-Opas Departments of Urology, andSearch for more papers by this authorJ. Aro, J. Aro Departments of Urology, andSearch for more papers by this authorP.J. Karhunen, P.J. Karhunen Department of Forensic Medicine and Research Unit of Clinical Chemistry, University of Tampere,Search for more papers by this authorJ. Lahtela, J. Lahtela Department of Internal Medicine, Tampere University Hospital, Tampere, andSearch for more papers by this authorP. Rissanen, P. Rissanen School of Public Health andSearch for more papers by this authorH. Juusela, H. Juusela Surgery, Jorvi Hospital, Helsinki University Central Hospital, Helsinki, FinlandSearch for more papers by this authorM. Hakama, M. Hakama Finnish Cancer Registry, Helsinki, School of Public Health andSearch for more papers by this author A. Auvinen, A. Auvinen School of Public Health andSearch for more papers by this author First published: 13 January 2004 https://doi.org/10.1111/j.1465-5101.2003.04397.xCitations: 34 P. Finne, Department of Clinical Chemistry, Biomedicum-Helsinki A424b, PO Box700, FIN-00029 HUS, Finland. e-mail: [email protected] Read the full textAboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onEmailFacebookTwitterLinkedInRedditWechat REFERENCES 1 Määttänen L, Auvinen A, Stenman U-H et al. European randomized study of prostate cancer screening: first-year results of the Finnish trial. Br J Cancer 1999; 79: 1210–4 2 De Koning HJ, Auvinen A, Berenguer Sanchez A et al. Large-scale randomized prostate cancer screening trials: program performances in the European Randomized Screening for Prostate Cancer trial and the Prostate, Lung, Colorectal and Ovary cancer trial. Int J Cancer 2002; 97: 237–44 3 Ornstein DK, Kang J. How to improve prostate biopsy detection of prostate cancer. Curr Urol Rep 2001; 2: 218–23 4 Van der Kwast TH, Lopes C, Santonja C et al. Guidelines for processing and reporting of prostatic needle biopsies. J Clin Pathol 2003; 56: 336–40 5 Määttänen L, Auvinen A, Stenman UH et al. Three-year results of the Finnish prostate cancer screening trial. J Natl Cancer Inst 2001; 93: 552–3 6 Carter HB, Morrell CH, Pearson JD et al. Estimation of prostatic growth using serial prostate-specific antigen measurements in men with and without prostate disease. Cancer Res 1992; 52: 3323–8 7 Stenman UH, Hakama M, Knekt P, Aromaa A, Teppo L, Leinonen J. Serum concentrations of prostate specific antigen and its complex with alpha 1-antichymotrypsin before diagnosis of prostate cancer. Lancet 1994; 344: 1594–8 8 Auvinen A, Määttänen L, Stenman UH et al. Lead-time in prostate cancer screening (Finland). Cancer Causes Control 2002; 13: 279–85 9 Lichtenstein P, Holm NV, Verkasalo PK et al. Environmental and heritable factors in the causation of cancer – analyses of cohorts of twins from Sweden, Denmark, and Finland. N Engl J Med 2000; 343: 78–85 10 Mäkinen T, Tammela TL, Stenman UH et al. Family history and prostate cancer screening with prostate-specific antigen. J Clin Oncol 2002; 20: 2658–63 11 Rietbergen JB, Kruger AE, Kranse R, Schröder FH. Complications of transrectal ultrasound-guided systematic sextant biopsies of the prostate: evaluation of complication rates and risk factors within a population-based screening program. Urology 1997; 49: 875–80 12 Djavan B, Waldert M, Zlotta A et al. Safety and morbidity of first and repeat transrectal ultrasound guided prostate needle biopsies: results of a prospective European prostate cancer detection study. J Urol 2001; 166: 856–60 13 Mäkinen T, Auvinen A, Hakama M, Stenman UH, Tammela TL. Acceptability and complications of prostate biopsy in population-based PSA screening versus routine clinical practice: a prospective, controlled study. Urology 2002; 60: 846–50 14 Kranse R, Beemsterboer P, Rietbergen J, Habbema D, Hugosson J, Schröder FH. Predictors for biopsy outcome in the European Randomized Study of Screening for Prostate Cancer (Rotterdam region). Prostate 1999; 39: 316–22 15 Virtanen A, Gomari M, Kranse R, Stenman UH. Estimation of prostate cancer probability by logistic regression: free and total prostate-specific antigen, digital rectal examination, and heredity are significant variables. Clin Chem 1999; 45: 987–94 16 Finne P, Finne R, Auvinen A et al. Predicting the outcome of prostate biopsy in screen-positive men by a multilayer perceptron network. Urology 2000; 56: 418–22 17 Finne P, Auvinen A, Aro J et al. Estimation of prostate cancer risk on the basis of total and free prostate-specific antigen, prostate volume and digital rectal examination. Eur Urol 2002; 41: 619–26 18 Finne P, Zhang W-M, Auvinen A et al. Use of the complex between prostate specific antigen and α1-protease inhibitor for screening prostate cancer. J Urol 2000; 164: 1956–60 19 Chan JM, Stampfer MJ, Giovannucci E et al. Plasma insulin-like growth factor-I and prostate cancer risk: a prospective study. Science 1998; 279: 563–6 20 Finne P, Auvinen A, Koistinen H et al. Insulin-like growth factor-I is not a useful marker of prostate cancer in men with elevated levels of prostate-specific antigen. J Clin Endocr Metab 2000; 85: 2744–7 21 Mäkinen T, Tammela TL, Hakama M et al. Prostate cancer screening within a prostate specific antigen range of 3–3.9 ng/ml a comparison of digital rectal examination and free prostate specific antigen as supplemental screening tests. J Urol 2001; 166: 1339–42 22 Isola J, Auvinen A, Poutiainen M et al. Predictors of biological aggressiveness of prostate specific antigen screening detected prostate cancer. J Urol 2001; 165: 1569–74 23 Ware JE Jr, Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care 1992; 30: 473–83 24 Litwin MS, Hays RD, Fink A, Ganz PA, Leake B, Brook RH. The UCLA Prostate Cancer Index: development, reliability, and validity of a health-related quality of life measure. Med Care 1998; 36: 1002–12 Citing Literature Volume92, Issues2December 2003Pages 22-26 ReferencesRelatedInformation
Referência(s)